Italian Journal of Pediatrics (Mar 2024)

Italian guidelines for the management of irritable bowel syndrome in children and adolescents

  • Giovanni Di Nardo,
  • Giovanni Barbara,
  • Osvaldo Borrelli,
  • Cesare Cremon,
  • Valentina Giorgio,
  • Luigi Greco,
  • Michele La Pietra,
  • Giovanni Marasco,
  • Licia Pensabene,
  • Marisa Piccirillo,
  • Claudio Romano,
  • Silvia Salvatore,
  • Michele Saviano,
  • Vincenzo Stanghellini,
  • Caterina Strisciuglio,
  • Renato Tambucci,
  • Rossella Turco,
  • Letizia Zenzeri,
  • Annamaria Staiano

DOI
https://doi.org/10.1186/s13052-024-01607-y
Journal volume & issue
Vol. 50, no. 1
pp. 1 – 23

Abstract

Read online

Abstract The irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID), whose prevalence has widely increased in pediatric population during the past two decades. The exact pathophysiological mechanism underlying IBS is still uncertain, thus resulting in challenging diagnosis and management. Experts from 4 Italian Societies participated in a Delphi consensus, searching medical literature and voting process on 22 statements on both diagnosis and management of IBS in children. Recommendations and levels of evidence were evaluated according to the grading of recommendations, assessment, development, and evaluation (GRADE) criteria. Consensus was reached for all statements. These guidelines suggest a positive diagnostic strategy within a symptom-based approach, comprehensive of psychological comorbidities assessment, alarm signs and symptoms’ exclusion, testing for celiac disease and, under specific circumstances, fecal calprotectin and C-reactive protein. Consensus also suggests to rule out constipation in case of therapeutic failure. Conversely, routine stool testing for enteric pathogens, testing for food allergy/intolerance or small intestinal bacterial overgrowth are not recommended. Colonoscopy is recommended only in patients with alarm features. Regarding treatment, the consensus strongly suggests a dietary approach, psychologically directed therapies and, in specific conditions, gut-brain neuromodulators, under specialist supervision. Conditional recommendation was provided for both probiotics and specific fibers supplementation. Polyethylene glycol achieved consensus recommendation for specific subtypes of IBS. Secretagogues and 5-HT4 agonists are not recommended in children with IBS-C. Certain complementary alternative therapies, antispasmodics and, in specific IBS subtypes, loperamide and rifaximin could be considered.

Keywords